上海谊众(688091) - 2024 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 8 million and 10 million yuan, representing a decrease of 93.81% to 95.05% compared to the previous year[4] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between 4 million and 6 million yuan, a decrease of 96.28% to 97.52% year-on-year[4] - The previous year's net profit attributable to shareholders of the parent company was 161.55 million yuan, and the net profit excluding non-recurring gains and losses was 161.07 million yuan[6] Product Sales and Market Access - The core product, paclitaxel polymer micelles, faced significant sales impact due to difficulties in hospital access and pharmacy configuration before entering the medical insurance directory[12] - The paclitaxel micelles were officially included in the medical insurance directory in January 2025, which will require price compensation for distributor inventory, directly affecting sales revenue and profit[12] - Following successful negotiations for medical insurance, the company has increased its investment in national sales layout, completing network access in all provinces and municipalities[12] - The paclitaxel micelles have entered the dual-channel management directory and separate payment list in over 20 provinces, with active hospital access work ongoing nationwide[12]